Results 111 to 120 of about 10,879 (228)

All-oral direct-acting Antiviral Therapy Against Hepatitis C Virus (HCV) in Human Immunodeficiency Virus/HCV– Coinfected Subjects in Real-World Practice: Madrid Coinfection Registry Findings [PDF]

, 2018
We evaluated treatment outcomes in a prospective registry of human immunodeficiency virus/hepatitis C virus (HCV)–coinfected patients treated with interferon-free direct-acting antiviral agent–based therapy in hospitals from the region of Madrid between
Abergel, Afdhal, Afdhal, Afdhal, Ahlen, Arias, Backus, Berenguer, Bhattacharya, Boesecke, European Association for the Study of the Liver, European Association for the Study of the Liver, Feld, Feld, Franchis, Gane, Gao, Hawkins, Hezode, Ingiliz, Ioannou, Kowdley, Kowdley, Kowdley, Leroy, Liang, Montes, Naggie, Nelson, Pawlotsky, Piroth, Poordad, Rockstroh, Saeed, Singh, Smith, Sogni, Sulkowski, Tapper, Terrault, Zeuzem, Zeuzem   +41 more
core   +3 more sources

Long‐Term Follow‐Up of Neuropsychiatric Symptoms After Sustained Virological Response to Interferon‐Free and Interferon‐Based Hepatitis C Virus Treatment

Journal of Viral Hepatitis, Volume 32, Issue 4, April 2025.
ABSTRACT Chronic hepatitis C virus (HCV) infection can be associated with neuropsychiatric symptoms like fatigue and cognitive impairment, independent of the liver status. The present study aims to assess changes in the pattern and extent of neuropsychological symptoms after successful treatment with interferon (IFN)‐based and IFN‐free therapy.
Meike Dirks, Ann‐Katrin Hennemann, Gerrit M. Grosse, Anika Beer, Henning Pflugrad, Kim Haag, Ramona Schuppner, Katja Deterding, Markus Cornberg, Heiner Wedemeyer, Karin Weissenborn   +10 more
wiley   +1 more source

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant

Annals of Hepatology, 2017
Introduction: Recurrence of HCV infection in patients with chronic hepatitis C virus (HCV) at the time of liver transplantation is nearly universal and reduces the likelihood of graft and patient survival.
Eric M. Yoshida, Paul Kwo, Kosh Agarwal, Christophe Duvoux, François Durand, Markus Peck-Radosavljevic, Leslie Lilly, Bernard Willems, Hugo Vargas, Princy Kumar, Robert S. Brown Jr., Yves Horsmans, Shampa De-Oertel, Sarah Arterburn, Hadas Dvory-Sobol, Diana M. Brainard, John G. McHutchison, Norah Terrault, Mario Rizzetto, Beat Müllhaupt   +19 more
doaj   +1 more source

Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use. [PDF]

, 2016
Background and aimsAll-oral interferon-free antivirals are highly effective in treating recurrent hepatitis C (HCV) infection in liver transplant (LT) recipients.
Bau, Sherona, Busuttil, Ronald W, Choi, Gina, Durazo, Francisco, El Kabany, Mohammed, Elashoff, David, Farid, Alexander, Grotts, Jonathan, Han, Steven, Jamal, Naadir, Jimenez, Melissa, Rheem, Justin, Saab, Sammy   +12 more
core   +2 more sources

Effectiveness and Safety of Glecaprevir/Pibrentasvir in Italian Children and Adolescents With Chronic Hepatitis C: A Real‐Word, Multicenter Study

Liver International, Volume 45, Issue 4, April 2025.
ABSTRACT Background & Aims Glecaprevir/Pibrentasvir (GLE/PIB) has been approved by the European Medicine Agency (EMA) and by the US Food and Drug Administration (US‐FDA) for the treatment of children and adolescents from 3 years of age with chronic hepatitis C virus (CHC) infection.
Mariangela Stinco, Chiara Rubino, Elisa Bartolini, Federica Nuti, Giulia Paolella, Gabriella Nebbia, Erika Silvestro, Silvia Garazzino, Emanuele Nicastro, Lorenzo D'Antiga, Chiara Zanchi, Laura Morra, Raffaele Iorio, Fabiola Di Dato, Giuseppe Maggiore, Maria Rita Sartorelli, Donatella Comparcola, Marta Stracuzzi, Vania Giacomet, Francesca Musto, Michele Pinon, Pierluigi Calvo, Ines Carloni, Federica Zallocco, Mara Cananzi, Sandra Trapani, Giuseppe Indolfi   +26 more
wiley   +1 more source

Era of direct acting antivirals in chronic hepatitis C: Who will benefit? [PDF]

, 2015
published_or_final_versio
Fung, JYY
core   +1 more source

The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions

MedComm, Volume 6, Issue 3, March 2025.
The malignant transformation from chronic viral hepatitis to hepatocellular carcinoma (HCC) involves intricate interactions among viral, host, and environmental factors. Key drivers of this transformation include viral integration, genomic instability, epigenetic modifications, oxidative stress, gut microbiota dysbiosis, chronic inflammation, immune ...
Huimin Yuan, Ruochen Xu, Senlin Li, Mengzhu Zheng, Qingyi Tong, Ming Xiang, Yonghui Zhang   +6 more
wiley   +1 more source

Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major [PDF]

, 2017
Chronic hepatitis C (CHC) significantly affects the prognosis of liver disease [1] and health related quality of life (HRQOL) in patients with β-thalassemia major [2, 3].
Biliotti, Elisa, Esvan, Rozenn, Franchi, Cristiana, Palazzo, Donatella, Serani, Marco, Silvestri, Alessandro M., Sorrentino, Francesco, Spaziante, Martina, Taliani, Gloria, Volpicelli, Lorenzo   +9 more
core   +1 more source

Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C

ClinicoEconomics and Outcomes Research, 2018
Katherine Heath1,2 1Mathematical Ecology Research Group, Department of Zoology, University of Oxford, Oxford OX1 3PS, UK; 2New College, Oxford OX1 3BN, UK Background: Cost-benefit analyses are crucial to inform treatment policies, particularly when the ...
Heath K
doaj  

Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients

Journal of Transplantation, 2018
Background. Since the introduction of direct antiviral agents (DAAs), morbidity of HCV has considerably decreased but still no guidelines have been formulated in renal transplant recipients (RTRs). We studied efficacy and tolerability of direct antiviral
Sourabh Sharma, Debabrata Mukherjee, Ranjith K. Nair, Bhaskar Datt, Ananth Rao   +4 more
doaj   +1 more source